aTyr Pharma, Inc. (NASDAQ:LIFE) Receives $19.00 Consensus Price Target from Brokerages

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.00.

A number of analysts have recently weighed in on the company. Roth Capital reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Friday, March 10th. Piper Sandler upped their price objective on aTyr Pharma from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, April 11th. Roth Mkm reissued a “buy” rating and issued a $9.00 target price on shares of aTyr Pharma in a research report on Monday, March 6th. Finally, StockNews.com began coverage on aTyr Pharma in a research report on Thursday, May 18th. They issued a “hold” rating on the stock.

Insider Buying and Selling

In other aTyr Pharma news, Director Paul Schimmel bought 200,000 shares of the firm’s stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $450,000.00. Following the completion of the purchase, the director now owns 313,023 shares of the company’s stock, valued at $704,301.75. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.14% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in aTyr Pharma in the fourth quarter valued at about $149,000. Royal Bank of Canada lifted its position in aTyr Pharma by 8,857.2% in the third quarter. Royal Bank of Canada now owns 48,727 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 48,183 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of aTyr Pharma by 87.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 40,965 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 19,150 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of aTyr Pharma during the 1st quarter valued at approximately $75,000. Finally, Virtu Financial LLC acquired a new stake in shares of aTyr Pharma during the 1st quarter valued at approximately $70,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

aTyr Pharma Trading Down 4.3 %

Shares of LIFE stock opened at $2.36 on Friday. aTyr Pharma has a 1 year low of $1.55 and a 1 year high of $4.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.75 and a quick ratio of 8.75. The stock’s 50 day simple moving average is $2.10 and its two-hundred day simple moving average is $2.18. The company has a market cap of $128.12 million, a PE ratio of -1.63 and a beta of 1.21.

aTyr Pharma (NASDAQ:LIFE – Get Rating) last announced its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.22. The firm had revenue of $10.39 million during the quarter, compared to the consensus estimate of $1.50 million. Research analysts predict that aTyr Pharma will post -1.46 earnings per share for the current year.

aTyr Pharma Company Profile

(Get Rating)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.